About
Chris joined Sanofi Ventures in 2017 with a background in life science and healthcare consulting. He previously spent three years as a management consultant at L.E.K. consulting where his work focused on corporate strategy, due diligence, commercial launch planning and asset valuation across the pharmaceutical, biotech, R&D and API manufacturing sectors. Chris currently serves on the Boards of AdvanCell Isotopes, i2O Therapeutics, Minervax, and Sudo Bio, and is a Board observer for Atalanta Therapeutics, Avilar Therapeutics, Matchpoint Therapeutics, and Nextpoint Therapeutics. He also led Sanofi Ventures’ investment in Curevo. Prior to a postdoctoral fellowship at Harvard University, Chris earned a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill as well as a B.S. in both Biology and Chemistry from Roger Williams University.
Sign up to see Christopher Gagliardi's full profile
Access investment thesis, focus areas, bio, and contact details for Christopher Gagliardi and 22,000+ other VC professionals.